AU2018269947B2 - Pyrrolo(2,3-c)pyridines and related analogs as LSD-1 inhibitors - Google Patents

Pyrrolo(2,3-c)pyridines and related analogs as LSD-1 inhibitors Download PDF

Info

Publication number
AU2018269947B2
AU2018269947B2 AU2018269947A AU2018269947A AU2018269947B2 AU 2018269947 B2 AU2018269947 B2 AU 2018269947B2 AU 2018269947 A AU2018269947 A AU 2018269947A AU 2018269947 A AU2018269947 A AU 2018269947A AU 2018269947 B2 AU2018269947 B2 AU 2018269947B2
Authority
AU
Australia
Prior art keywords
cancer
optionally substituted
group
cell
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018269947A
Other languages
English (en)
Other versions
AU2018269947A1 (en
Inventor
Zhuo Chen
Liyue HUANG
Liu Liu
Shaomeng Wang
Chao-Yie Yang
Dengyou ZHANG
Canhui ZHENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of AU2018269947A1 publication Critical patent/AU2018269947A1/en
Application granted granted Critical
Publication of AU2018269947B2 publication Critical patent/AU2018269947B2/en
Priority to AU2022200197A priority Critical patent/AU2022200197A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2018269947A 2017-05-15 2018-05-15 Pyrrolo(2,3-c)pyridines and related analogs as LSD-1 inhibitors Active AU2018269947B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022200197A AU2022200197A1 (en) 2017-05-15 2022-01-13 Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762506349P 2017-05-15 2017-05-15
US62/506,349 2017-05-15
PCT/US2018/032619 WO2018213211A1 (en) 2017-05-15 2018-05-15 Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022200197A Division AU2022200197A1 (en) 2017-05-15 2022-01-13 Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors

Publications (2)

Publication Number Publication Date
AU2018269947A1 AU2018269947A1 (en) 2019-12-19
AU2018269947B2 true AU2018269947B2 (en) 2021-10-14

Family

ID=62685119

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018269947A Active AU2018269947B2 (en) 2017-05-15 2018-05-15 Pyrrolo(2,3-c)pyridines and related analogs as LSD-1 inhibitors
AU2022200197A Abandoned AU2022200197A1 (en) 2017-05-15 2022-01-13 Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022200197A Abandoned AU2022200197A1 (en) 2017-05-15 2022-01-13 Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors

Country Status (6)

Country Link
US (1) US11168082B2 (enExample)
EP (1) EP3628044B1 (enExample)
JP (1) JP7352284B2 (enExample)
CN (1) CN110914265B (enExample)
AU (2) AU2018269947B2 (enExample)
WO (1) WO2018213211A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11944614B2 (en) * 2018-05-15 2024-04-02 Regents Of The University Of Michigan Imidazo[4,5-c]pyridine compounds as LSD-1 inhibitors
US20220151998A1 (en) 2019-03-20 2022-05-19 Oryzon Genomics, S.A. Methods of treating borderline personality disorder
US20220151999A1 (en) 2019-03-20 2022-05-19 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
US20220227763A1 (en) 2019-05-29 2022-07-21 Syngenta Crop Protection Ag Microbiocidal derivatives
CN112451671B (zh) * 2020-12-02 2021-11-02 武汉大学 KDM1A在抑制RNA病毒刺激下干扰素IFNβ表达中的应用
CA3231846A1 (en) 2021-04-08 2022-10-13 Tamara Maes Combinations of lsd1 inhibitors for treating myeloid cancers
CN116102533A (zh) * 2021-11-11 2023-05-12 中国科学院上海药物研究所 一种芳杂环类化合物及其应用
JP2025503099A (ja) * 2022-01-25 2025-01-30 成都苑▲東▼生物制▲薬▼股▲ふん▼有限公司 ピリジン系誘導体、その製造方法及び使用
EP4522136A1 (en) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
CN119497613A (zh) 2022-05-09 2025-02-21 奥莱松基因组股份有限公司 使用lsd1抑制剂治疗nf1-突变肿瘤的方法
IL318791A (en) * 2022-08-22 2025-04-01 Redx Pharma Ltd Pyridopyrazoles as DDR'S inhibitors for the treatment of lipid disorders and cancer
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
WO2024208187A1 (zh) * 2023-04-03 2024-10-10 上海复星医药（集团）股份有限公司 氮杂芳基化合物及其作为lsd1抑制剂的用途
WO2025072637A1 (en) * 2023-09-28 2025-04-03 The Regents Of The University Of Michigan Oxygenated heterocyclic lsd-1 inhibitors and related methods of use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079521A2 (en) * 2006-11-01 2008-07-03 Vertex Pharmaceuticals Incorporated Tricyclic heteroaryl compounds useful as inhibitors of janus kinase
KR20150024669A (ko) * 2013-08-27 2015-03-09 제일모직주식회사 화합물, 이를 포함하는 유기발광소자 및 상기 유기발광소자를 포함하는 표시장치
WO2015153683A1 (en) * 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
US20160009720A1 (en) * 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016161282A1 (en) * 2015-04-03 2016-10-06 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
WO2016201266A1 (en) * 2015-06-11 2016-12-15 Usher Iii Initiative, Inc. Methods of treating or preventing a proteopathy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JP2002507996A (ja) * 1997-07-03 2002-03-12 デュポン ファーマシューティカルズ カンパニー 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
US6365589B1 (en) * 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
CA2444882A1 (en) * 2001-04-30 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of gsk-3 and crystal structures of gsk-3.beta. protein and protein complexes
BRPI0610828A2 (pt) * 2005-05-16 2010-07-27 Irm Llc compostos e composições como inibidores de proteìna quinase
JP2009523812A (ja) * 2006-01-19 2009-06-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 融合へテロ二環式キナーゼ阻害剤
MX2009010886A (es) * 2007-04-12 2009-12-14 Hoffmann La Roche Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa.
WO2008138184A1 (fr) * 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
JP2010537998A (ja) * 2007-08-27 2010-12-09 ワイス・エルエルシー イミダゾピリジン類似体、およびＷｎｔ−βカテニン細胞メッセージ伝達系のアゴニストとしてのその使用
GB201008134D0 (en) * 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
KR101789129B1 (ko) * 2010-06-30 2017-11-20 후지필름 가부시키가이샤 신규 니코틴아미드 유도체 또는 그 염
PL3080100T3 (pl) * 2013-12-11 2023-03-06 Celgene Quanticel Research, Inc. Inhibitory lizyno-specyficznej demetylazy-1
KR102421235B1 (ko) 2014-02-13 2022-07-15 인사이트 코포레이션 Lsd1 저해제로서 사이클로프로필아민
NZ723203A (en) 2014-02-13 2020-08-28 Incyte Corp Cyclopropylamines as lsd1 inhibitors
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
AR110963A1 (es) * 2017-02-07 2019-05-22 Dae Woong Pharma Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079521A2 (en) * 2006-11-01 2008-07-03 Vertex Pharmaceuticals Incorporated Tricyclic heteroaryl compounds useful as inhibitors of janus kinase
KR20150024669A (ko) * 2013-08-27 2015-03-09 제일모직주식회사 화합물, 이를 포함하는 유기발광소자 및 상기 유기발광소자를 포함하는 표시장치
WO2015153683A1 (en) * 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
US20160009720A1 (en) * 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016161282A1 (en) * 2015-04-03 2016-10-06 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
WO2016201266A1 (en) * 2015-06-11 2016-12-15 Usher Iii Initiative, Inc. Methods of treating or preventing a proteopathy

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 1476063-00-9; STN Entry Date 18 November 2013; 1H-Pyrrolo[2,3-c]pyridine, 4-bromo-1-[2-(1-pyrrolidinyl)ethyl]- *
MITKIN O D ET AL, TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, (2001-02-25), vol. 57, no. 9, doi:10.1016/S0040-4020(00)01162-5, ISSN 0040-4020, pages 1827 - 1831 *
MOULD DANIEL P ET AL, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, (2017-05-08), vol. 27, no. 14, doi:10.1016/J.BMCL.2017.05.018, ISSN 0960-894X, pages 3190 - 3195 *
PubChem Compound Summary for ClD 126554614 (4-(3-Fluorophenyl)-1H-pyrrolo[2,3-c]pyridine), National Center for Biotechnology Information, created on 22 April 2017 <URL: https://pubchem.ncbi.nlm.nih.gov/compound/126554614> *
PubChem Compound Summary for ClD 66714572 (4-(1H-pyrrolo[2,3-c]pyridin-4-yl)aniline), National Center for Biotechnology Information, created on 30 Nov 2012 <URL: https://pubchem.ncbi.nlm.nih.gov/compound/66714572> *
PubChem Compound Summary for ClD 68762939 (2-(1H-pyrrolo[2,3-c]pyridin-4-yl)benzonitrile), National Center for Biotechnology Information, created on 30 Nov 2012 <URL: https://pubchem.ncbi.nlm.nih.gov/compound/68762939> *
PubChem Compound Summary for ClD 76847332 (5-Chloro-4-fluoro-1H-pyrrolo[2,3-c]pyridine), National Center for Biotechnology Information, created on 6 August 2014 <URL: https://pubchem.ncbi.nlm.nih.gov/compound/76847332> *
PubChem Compound Summary for ClD 91345 (4-Chloroindole), National Center for Biotechnology Information, created on 26 March 2005 <URL: https://pubchem.ncbi.nlm.nih.gov/compound/91345> *
REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (1984-11-16), Database accession no. 17374-26-4 *
REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (2003-09-02), Database accession no. 577779-57-8 *
REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (2007-11-26), Database accession no. 955978-88-8 *
REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (2008-12-08), Database accession no. 1082041-85-7 *
REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (2008-12-11), Database accession no. 1083096-61-0 *

Also Published As

Publication number Publication date
WO2018213211A1 (en) 2018-11-22
US20200157091A1 (en) 2020-05-21
AU2022200197A1 (en) 2022-02-10
AU2018269947A1 (en) 2019-12-19
CN110914265B (zh) 2022-12-23
EP3628044A1 (en) 2020-04-01
CN110914265A (zh) 2020-03-24
JP2020519667A (ja) 2020-07-02
US11168082B2 (en) 2021-11-09
EP3628044B1 (en) 2023-11-22
JP7352284B2 (ja) 2023-09-28

Similar Documents

Publication Publication Date Title
AU2022200197A1 (en) Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors
US11045448B2 (en) Piperidines as covalent menin inhibitors
US20220411432A1 (en) Mdm2 protein degraders
US20210198237A1 (en) Piperidines as menin inhibitors
AU2017219627B2 (en) Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors
US20240150360A1 (en) Small Molecule Degraders of CBP/p300 Proteins
WO2020103864A1 (en) Macrocyclic indoles as mcl-1 inhibitors
US10307407B2 (en) 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors
AU2014249192A1 (en) BET bromodomain inhibitors and therapeutic methods using the same
US11944614B2 (en) Imidazo[4,5-c]pyridine compounds as LSD-1 inhibitors
US20210115018A1 (en) Piperidine compounds as covalent menin inhibitors
US11046709B2 (en) Fused 1,4-diazepines as BET bromodomain inhibitors
HK40026020B (en) Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors
HK40026020A (en) Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors
HK40022861B (en) Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors